Low-dose radiation plus immunotherapy to shrink esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus that has not spread to distant organs (except possibly to lymph nodes near the collarbone).
- Your cancer is considered unresectable or borderline resectable because it has grown into nearby structures or cannot be safely removed.
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your blood counts, liver and kidney function, and heart function meet specific safety levels.
- You are willing to use contraception during the study and for 6 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests whether low-dose radiation can help people with advanced esophageal cancer that has stopped responding to standard chemotherapy plus immunotherapy. It aims to see if adding radiation can shrink tumors or slow the disease.
Hear when a new Immune Checkpoint Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.